Marietta Investment Partners LLC Buys 12,130 Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Marietta Investment Partners LLC boosted its stake in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 234.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,300 shares of the company’s stock after purchasing an additional 12,130 shares during the quarter. Marietta Investment Partners LLC’s holdings in Dr. Reddy’s Laboratories were worth $273,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in RDY. EverSource Wealth Advisors LLC boosted its position in Dr. Reddy’s Laboratories by 423.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company’s stock valued at $29,000 after purchasing an additional 1,507 shares in the last quarter. POM Investment Strategies LLC boosted its position in Dr. Reddy’s Laboratories by 400.0% during the fourth quarter. POM Investment Strategies LLC now owns 2,275 shares of the company’s stock valued at $36,000 after purchasing an additional 1,820 shares in the last quarter. Farther Finance Advisors LLC boosted its holdings in Dr. Reddy’s Laboratories by 461.0% in the fourth quarter. Farther Finance Advisors LLC now owns 2,547 shares of the company’s stock worth $40,000 after acquiring an additional 2,093 shares in the last quarter. Allworth Financial LP boosted its holdings in Dr. Reddy’s Laboratories by 447.8% in the fourth quarter. Allworth Financial LP now owns 2,728 shares of the company’s stock worth $41,000 after acquiring an additional 2,230 shares in the last quarter. Finally, Sierra Ocean LLC acquired a new stake in Dr. Reddy’s Laboratories in the fourth quarter worth about $43,000. Institutional investors own 3.85% of the company’s stock.

Dr. Reddy’s Laboratories Trading Up 1.1 %

Dr. Reddy’s Laboratories stock opened at $13.73 on Friday. The company has a quick ratio of 1.38, a current ratio of 1.92 and a debt-to-equity ratio of 0.02. Dr. Reddy’s Laboratories Limited has a 52 week low of $12.50 and a 52 week high of $16.89. The company has a market capitalization of $11.46 billion, a price-to-earnings ratio of 21.86 and a beta of 0.48. The stock has a 50-day moving average price of $13.66 and a 200 day moving average price of $14.71.

Dr. Reddy’s Laboratories (NYSE:RDY) last released its earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a return on equity of 17.87% and a net margin of 17.25%. Sell-side analysts anticipate that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have weighed in on RDY. StockNews.com downgraded Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 6th. Nomura downgraded Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th.

Dr. Reddy’s Laboratories Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.